Sixty Million Americans Are Struggling with Mental Illness. The Life-Changing Treatment Most Americans Don’t Know Exists

Nearly one in four American adults lives with a mental health condition. That’s more than 60 million people — veterans, teenagers, working parents, executives — navigating depression, anxiety, OCD, and addiction, often without adequate treatment. For most, the only option they’ve been offered is medication. And for millions, medication hasn’t worked. Up to two-thirds of depression patients don’t achieve remission from their first antidepressant. After multiple tries, 30 to 40 percent still see no meaningful improvement.

Patients are searching for something different — treatment that is noninvasive, doesn’t require medication, fits into daily life, and actually targets the root cause of their condition rather than masking symptoms. That treatment exists. It’s called Deep TMS, and the company that invented, patented, and clinically validated it is BrainsWay.

BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS™) uses magnetic fields to stimulate the brain networks where psychiatric disorders actually live. That distinction matters: depression, OCD, and addiction are network disorders — multiple brain regions falling out of sync — not single-point problems. Most TMS devices only reach a small area on the brain’s surface. BrainsWay’s patented H-Coil technology, originally developed at the U.S. National Institutes of Health, reaches deeper and broader — engaging the circuits that other systems simply cannot.

The clinical proof is unmatched. BrainsWay is the first and only TMS company to hold three distinct FDA-cleared indications — major depressive disorder (including anxious depression), OCD, and smoking addiction — each backed by its own large-scale pivotal trial. In 2025, BrainsWay became the first TMS device cleared for adolescent depression, and with its 2024 FDA clearance for late-life depression in adults ages 65+, now covers patients ages 15 to 86—making it the TMS choice with the broadest age-range coverage. More than 60 clinical trials worldwide. More than 1,700 clinics across the U.S. No other platform comes close.

And BrainsWay isn’t standing still. Its SWIFT™ Accelerated protocol, validated in Brain Stimulation in 2026, cuts the acute treatment phase by 70 percent — without compromising results. For patients who can’t afford weeks of daily sessions, that changes everything. Beyond the clinic, BrainsWay’s investment in Neurolief is bringing noninvasive brain stimulation into patients’ homes — making effective treatment accessible where and when people actually need it.

Mental illness is the leading cause of disability worldwide. The cost of undertreated mental health in America runs into hundreds of billions of dollars a year. But the real cost isn’t economic — it’s human. It’s the teenager who has stopped leaving the house, the veteran who has given up on treatment, the parent who doesn’t believe recovery is possible.

BrainsWay exists to change that equation. The science is proven. The technology is here. The only question is how many more people have to suffer before the rest of the system catches up.